When ACI becomes the right choice for ankle cartilage damage

Most patients arriving at ACI have either exceeded the size threshold where simpler surgery is appropriate, or they have tried microfracture and found it insufficient. Autologous chondrocyte implantation (ACI) and its matrix-based variant MACI are indicated for osteochondral lesions of the talus (OLT) larger than 150 mm², or as salvage following failed bone marrow stimulation — most commonly microfracture.

For smaller lesions, microfracture is typically attempted first. It produces fibrocartilage rather than hyaline-like cartilage — a mechanically weaker repair tissue that is less well suited to the load demands of the ankle joint. ACI and MACI target hyaline-like regeneration, which is biomechanically superior for long-term function. When microfracture succeeds, escalation is unnecessary. When it does not, ACI provides a validated second-stage pathway.

Some patients may be identifiable as poor microfracture candidates before a first procedure fails. A 2025 study identified the 'jumping dot sign' — a specific MRI pattern within cystic OLTs — as a predictor of inferior clinical outcomes and higher subchondral cyst recurrence after bone marrow stimulation. Patients with this sign may warrant earlier escalation to ACI rather than proceeding through an unsuccessful first attempt.

ACI is a planned, consultant-led pathway rather than emergency surgery. It requires two stages — an initial arthroscopic cartilage biopsy and, typically four to six weeks later, open implantation — which allows adequate time for thorough assessment and shared decision-making before committing to treatment.

What an osteochondral lesion of the talus actually involves

The talus transfers the full weight of the body through a joint surface roughly the size of a postage stamp. An osteochondral lesion of the talus (OLT) involves damage not just to this cartilage surface but to the bone immediately beneath it — the subchondral bone — making it a compound injury with distinct structural implications.

Cartilage has no blood supply of its own. That avascularity means it cannot mount the cellular repair response that heals most other tissues; focal defects tend to enlarge rather than resolve, and the tenuous vascular supply to the talus specifically adds to this challenge.

Lesion severity is graded by depth. Shallow defects confined to the cartilage layer behave differently from deeper ones that breach the subchondral bone plate beneath. This distinction, reflected in classifications such as the ICRS grading system, shapes which repair strategy is appropriate — and at what defect size a more demanding procedure becomes necessary.

Location adds a further layer of complexity. The majority of OLTs affect the posteromedial talar dome — the inner, rear portion of the joint surface — which sits partly behind the medial malleolus (the bony inner-ankle prominence). Accessing this region surgically is considerably more demanding than approaching lesions on the outer edge, a factor that directly influences procedural planning.

Symptoms — a deep ankle ache, intermittent swelling, locking, or a sense of giving way — can mimic sprains or tendon problems and are often managed conservatively for a period. In structurally significant lesions, they typically persist or worsen without repair.

The two-stage ACI and MACI procedure for the ankle

Treatment unfolds across two planned stages, separated by a laboratory phase that sits at the heart of what makes ACI distinctive.

Stage one: the biopsy

During the first operation, a small sample of healthy cartilage — typically harvested from a non-weight-bearing region of the knee — is removed through an arthroscope. The sample contains living chondrocytes (the cells responsible for maintaining cartilage), which are then sent to a specialist laboratory. Over the following four to six weeks, those cells are expanded into the larger population needed to fill the ankle defect.

Stage two: implantation

The second operation is open rather than arthroscopic, because the cells must be secured precisely within the prepared defect. In first-generation ACI, the cultured cells are injected beneath a periosteal patch — a thin sliver of membrane harvested from the patient's own shin bone — which is then sutured over the defect to contain them. MACI replaces this step: the expanded chondrocytes are pre-seeded onto a ready-made Type I/III collagen scaffold before surgery, and that membrane is fixed into position using fibrin glue. There is no periosteal harvest, no suturing of a patch, and no secondary donor site, which reduces complexity and associated morbidity. Both approaches remain two-stage procedures — the meaningful difference is in how the cells are delivered and secured at implantation.

The osteotomy requirement

Posteromedial lesions — the most common OLT location — sit partly behind the medial malleolus, the bony prominence on the inner ankle. Gaining clear surgical access often requires a medial malleolar osteotomy: the surgeon temporarily cuts and displaces that bony prominence to open the joint, then fixes it back with screws once implantation is complete. This is standard technique for this anatomy, but it does add a layer of complexity and extends the overall recovery period. Patients considering ACI or MACI for a posteromedial lesion should factor this in when discussing timelines with their consultant.

Published MACI series have treated mean defect areas of around 204 mm² — underscoring that this is a technique built for larger, structurally complex lesions rather than incidental findings.

What 20 years of follow-up data actually shows

Twenty years is a meaningful test. A 2024 study of first-generation ACI at the talus — with minimum 20-year follow-up across nine patients — found that AOFAS ankle-hindfoot scores improved from 40.4 before surgery to 82.7 at final review (p < 0.0005), while pain NRS fell from 7.8 to 4.8 over the same period. That sustained improvement across two decades addresses the central concern for any patient committing to a two-stage procedure: will the repair hold?

A complementary MACI series of 15 patients, followed for a mean of 12.9 years, showed similarly durable gains — AOFAS rising from 60 preoperatively to 84, with FAAM Activities of Daily Living scores reaching 89% at 12 years. One finding from this series merits particular attention: MOCART MRI scores — a validated measure of how the repair tissue appears on imaging — did not correlate with clinical function (p = 0.86). In plain terms, a repair that looks imperfect on a scan may still produce excellent functional recovery. Imaging appearance and patient-reported outcome are measuring different things, and the latter is what matters most in daily life.

Both studies contribute to a broader 2021 systematic review and meta-analysis that formally established the efficacy and safety of ACI for talar osteochondral defects, pooling case-series results to provide a more robust evidence anchor than any single cohort can offer alone.

The underlying studies are predominantly Level IV case series. No high-quality randomised controlled trials have directly compared ACI or MACI against single-stage alternatives such as AMIC. That is a genuine limitation, though the consistency of functional improvement across multiple long-term cohorts — sustained to 20 years in the case of first-generation ACI — provides meaningful reassurance about durability.

How ACI fits alongside other ankle cartilage procedures

The choice of procedure depends heavily on lesion size, the state of the underlying bone, and whether a previous operation has already been attempted — rather than on any single technique being universally superior.

For defects under 150 mm², microfracture and mosaicplasty remain appropriate first-line options. A 47-patient study comparing both techniques at 26-month mean follow-up found statistically significant AOFAS gains from each — mosaicplasty from 38.84 to 78.79, microfracture to a similarly large effect — which places ACI and MACI not in competition at this lesion size but as the natural next step if those repairs fail, or as the primary choice when a defect exceeds that threshold from the outset.

For the largest lesions with substantial subchondral bone involvement, two alternatives become relevant. Multi-plug autologous osteochondral transplantation (AOT) achieved AOFAS scores of 97.36 at 12 months in a 40-patient series, though the follow-up window is shorter than the ACI data reviewed earlier. Fresh osteochondral allograft, pooling 191 patients across 12 studies, demonstrated 86.6% graft survival at a mean of 56.8 months; it is typically considered when subchondral bone loss is too extensive for cell-based repair alone.

AMIC (autologous matrix-induced chondrogenesis) offers a single-stage, lower-resource route that avoids the two-stage commitment of ACI. No randomised trial has yet compared the two directly, so the choice between them currently rests on indirect evidence and individual clinical factors.

Age introduces a further consideration. In a cohort of 27 adolescent patients (mean age 16.9 years), the re-operation rate after primary OLT surgery reached 25.9% at median 31 months, with ACI employed as a salvage procedure in nine of those cases. Long-term paediatric-specific ACI outcomes remain sparsely documented, so management decisions in younger patients warrant particular discussion with a specialist.

Recovery timeline and what to expect from the MSK Doctors pathway

Recovery from ACI at the ankle follows the procedure's own two-stage logic. The biopsy is relatively minor, but it starts a clock: laboratory chondrocyte expansion takes approximately four to six weeks before cells are ready to implant — an interval to factor into planning from the outset, not to treat as an unexpected pause between appointments.

The implantation, particularly when medial malleolar osteotomy is required for access to a posteromedial lesion, demands structured rehabilitation. Full return to sport or demanding physical activity typically takes 12 months or longer. For suitable candidates, that commitment is proportionate to the durability the evidence supports.

MRI scans are used to monitor graft incorporation during follow-up, though imaging appearance and functional recovery do not always move in step — MOCART scores in the long-term MACI series were uncorrelated with clinical function (p = 0.86). How the ankle performs day to day remains the primary measure, not how the repair tissue looks on a scan.

MSK Doctors consultants assess and plan ACI cases without a GP referral, with consultations and diagnostics available at the Sleaford and Grantham sites. London-based patients can access equivalent specialist care through the London Cartilage Clinic. The most useful preparation for a first appointment is a clear account of previous treatments and current ankle function — that clinical history, more than any single scan result, frames the decisions that follow. Appointments can be booked at mskdoctors.com.

1. [1] Jumping Dot Sign: A New Radiological Sign Predicting Inferior Clinical Outcome and Higher Cyst Recurrence Following Bone Marrow Stimulation for Cystic Osteochondral Lesions of the Talus. (2025). https://doi.org/10.1177/23259671251358377 https://doi.org/10.1177/23259671251358377
2. [2] The Use of ACI/MACI to Restore Osteochondral Defects in the Ankle. (2020). https://doi.org/10.1007/978-3-030-29231-7_10 https://doi.org/10.1007/978-3-030-29231-7_10
3. [3] Effects of Losartan and Fisetin on Microfracture-Mediated Cartilage Repair of Ankle Cartilage in a Rabbit Model. (2024). https://doi.org/10.1177/03635465241285902 https://doi.org/10.1177/03635465241285902
4. [4] The Comparison of the Results of Microfracture and Mosaicplasty in Talus Osteochondral Lesions. (2024). https://doi.org/10.7759/cureus.61217 https://doi.org/10.7759/cureus.61217
5. [5] Matrix-Induced Autologous Chondrocyte Implantation (MACI) Grafting for Osteochondral Lesions of the Talus. (2020). https://doi.org/10.1177/1071100720935110 https://doi.org/10.1177/1071100720935110
6. [6] Efficacy and safety of autologous chondrocyte implantation for osteochondral defects of the talus: a systematic review and meta-analysis. (2021). https://doi.org/10.1007/s00402-021-03990-1 https://doi.org/10.1007/s00402-021-03990-1
7. [7] Autologous chondrocyte implantation for the treatment of osteochondral lesions of the talus: What happens after 20 years?. (2024). https://doi.org/10.1016/j.fas.2024.04.007 https://doi.org/10.1016/j.fas.2024.04.007
8. [8] Topical Review: MACI as an Emerging Technology for the Treatment of Talar Osteochondral Lesions. (2017). https://doi.org/10.1177/1071100717711482 https://doi.org/10.1177/1071100717711482
9. [9] A Systematic Review of Fresh Osteochondral Allograft Transplantation for Osteochondral Lesions of the Talus. (2020). https://doi.org/10.1177/2473011420S00382 https://doi.org/10.1177/2473011420S00382